Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Income towards Parent Company: 2015-2025

Historic Income towards Parent Company for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to -$25.1 million.

  • Editas Medicine's Income towards Parent Company rose 59.58% to -$25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.6 million, marking a year-over-year increase of 6.13%. This contributed to the annual value of -$237.1 million for FY2024, which is 56.38% down from last year.
  • Editas Medicine's Income towards Parent Company amounted to -$25.1 million in Q3 2025, which was up 51.21% from -$51.5 million recorded in Q2 2025.
  • Editas Medicine's Income towards Parent Company's 5-year high stood at -$18.9 million during Q4 2023, with a 5-year trough of -$75.7 million in Q1 2025.
  • Moreover, its 3-year median value for Income towards Parent Company was -$47.5 million (2023), whereas its average is -$49.2 million.
  • As far as peak fluctuations go, Editas Medicine's Income towards Parent Company tumbled by 524.32% in 2021, and later soared by 68.95% in 2023.
  • Over the past 5 years, Editas Medicine's Income towards Parent Company (Quarterly) stood at -$41.4 million in 2021, then tumbled by 46.58% to -$60.7 million in 2022, then spiked by 68.95% to -$18.9 million in 2023, then slumped by 140.68% to -$45.4 million in 2024, then spiked by 59.58% to -$25.1 million in 2025.
  • Its Income towards Parent Company was -$25.1 million in Q3 2025, compared to -$51.5 million in Q2 2025 and -$75.7 million in Q1 2025.